Emricasan is an investigational drug.
There have been 15 clinical trials for Emricasan.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2013.
The most common disease conditions in clinical trials are Fibrosis, Liver Cirrhosis, and Fatty Liver. The leading clinical trial sponsors are Conatus Pharmaceuticals Inc., Histogen, and University of Alberta.